Weekly injections of PRO 140 in combination with optimized ART shows HIV-1 viral suppression

(American Society for Microbiology) Results from a pivotal trial of PRO 140, a new HIV therapy, show that PRO 140 is an effective, long-acting therapeutic in combination with antiretroviral treatment (ART) for previously treated HIV-1 infected patients. This is an ongoing randomized, double-blind, placebo-controlled trial. The research is presented at ASM Microbe, the annual meeting of the American Society for Microbiology, held from June 7-11 in Atlanta, Ga.